KR102377742B1 - 암치료약 - Google Patents

암치료약 Download PDF

Info

Publication number
KR102377742B1
KR102377742B1 KR1020207021029A KR20207021029A KR102377742B1 KR 102377742 B1 KR102377742 B1 KR 102377742B1 KR 1020207021029 A KR1020207021029 A KR 1020207021029A KR 20207021029 A KR20207021029 A KR 20207021029A KR 102377742 B1 KR102377742 B1 KR 102377742B1
Authority
KR
South Korea
Prior art keywords
cancer
acid
salts
jph203
pharmacologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207021029A
Other languages
English (en)
Korean (ko)
Other versions
KR20200101960A (ko
Inventor
히토시 엔도
준지 후루세
이사오 오카야스
마이클 에프 웸피
Original Assignee
제이 파마 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이 파마 가부시끼가이샤 filed Critical 제이 파마 가부시끼가이샤
Publication of KR20200101960A publication Critical patent/KR20200101960A/ko
Application granted granted Critical
Publication of KR102377742B1 publication Critical patent/KR102377742B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
KR1020207021029A 2017-12-28 2018-08-01 암치료약 Active KR102377742B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017253385 2017-12-28
JPJP-P-2017-253385 2017-12-28
PCT/JP2018/028887 WO2019130637A1 (ja) 2017-12-28 2018-08-01 がん治療薬

Publications (2)

Publication Number Publication Date
KR20200101960A KR20200101960A (ko) 2020-08-28
KR102377742B1 true KR102377742B1 (ko) 2022-03-22

Family

ID=67066788

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207021029A Active KR102377742B1 (ko) 2017-12-28 2018-08-01 암치료약

Country Status (10)

Country Link
US (1) US12458628B2 (https=)
EP (1) EP3733175B1 (https=)
JP (4) JP6546367B1 (https=)
KR (1) KR102377742B1 (https=)
CN (1) CN111491632A (https=)
BR (1) BR112020012766A2 (https=)
CA (1) CA3083343C (https=)
ES (1) ES2960392T3 (https=)
MX (1) MX2020006678A (https=)
WO (1) WO2019130637A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11899019B2 (en) * 2017-11-07 2024-02-13 J-Pharma Co., Ltd. Method for predicting efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy
PH12021552866A1 (en) 2019-05-14 2022-11-07 Tyme Inc Compositions and methods for treating cancer
CN112336859A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 通过抑制t细胞摄取氨基酸治疗阿尔茨海默病的方法
WO2021146506A2 (en) * 2020-01-17 2021-07-22 Tyme, Inc. Compositions and methods for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2022102687A1 (ja) * 2020-11-11 2022-05-19 ジェイファーマ株式会社 がん治療剤
TW202434224A (zh) 2023-01-16 2024-09-01 日商Ｊ製藥股份有限公司 膽道癌治療劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008081537A1 (ja) * 2006-12-28 2008-07-10 Human Cell Systems, Inc. Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体、それを含有するｌａｔ１阻害活性剤及びその製造方法
US20160279103A1 (en) 2014-05-15 2016-09-29 J-Pharma Co., Ltd. An anticancer agent composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017155023A (ja) 2016-03-04 2017-09-07 ジェイファーマ株式会社 Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤
US11899019B2 (en) 2017-11-07 2024-02-13 J-Pharma Co., Ltd. Method for predicting efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy
US20220288035A1 (en) 2019-08-30 2022-09-15 J-Pharma Co., Ltd. A pharmaceutical composition for treating cancer used for a patient having specific genetic marker
WO2022102687A1 (ja) 2020-11-11 2022-05-19 ジェイファーマ株式会社 がん治療剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008081537A1 (ja) * 2006-12-28 2008-07-10 Human Cell Systems, Inc. Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体、それを含有するｌａｔ１阻害活性剤及びその製造方法
US20160279103A1 (en) 2014-05-15 2016-09-29 J-Pharma Co., Ltd. An anticancer agent composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Science, 101(10), 173-179, 2010.*

Also Published As

Publication number Publication date
US12458628B2 (en) 2025-11-04
JP6734971B2 (ja) 2020-08-05
CA3083343A1 (en) 2019-07-04
JP2019151672A (ja) 2019-09-12
BR112020012766A2 (pt) 2020-12-01
CA3083343C (en) 2022-04-26
EP3733175B1 (en) 2023-10-04
ES2960392T3 (es) 2024-03-04
JPWO2019130637A1 (ja) 2019-12-26
KR20200101960A (ko) 2020-08-28
JP2023101705A (ja) 2023-07-21
EP3733175A1 (en) 2020-11-04
WO2019130637A1 (ja) 2019-07-04
MX2020006678A (es) 2020-08-31
CN111491632A (zh) 2020-08-04
JP2020073586A (ja) 2020-05-14
US20200405695A1 (en) 2020-12-31
JP6546367B1 (ja) 2019-07-17
JP7541400B2 (ja) 2024-08-28
EP3733175A4 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
KR102377742B1 (ko) 암치료약
Renault-Mahieux et al. Co-encapsulation of fisetin and cisplatin into liposomes: Stability considerations and in vivo efficacy on lung cancer animal model
US11141421B2 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
CN115400115B (zh) 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途
EP3873510B1 (en) Thiostrepton and vitamin e-tpgs for treating cancer
CN116265015A (zh) 多西他赛白蛋白组合物与vegf抑制剂或vegfr抑制剂的组合及其用途
Jiménez Gallo et al. Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine
KR20090050070A (ko) 항종양제를 포함하는 수성 제제
WO2019164010A1 (ja) 膀胱がん用抗腫瘍剤および膀胱がんの処置方法
HK40083164B (zh) 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途
HK40083164A (en) Combination of docetaxel albumin composition and immune checkpoint inhibitor and use thereof
WO2025232873A1 (zh) 多西他赛白蛋白组合物治疗胃癌或胃食管结合部癌的用途
CN119454681A (zh) 肾型谷氨酰胺酶抑制剂及其联合用药的用途
KR20240044460A (ko) 뇌암 치료 방법
HK40055088B (en) Thiostrepton and vitamin e-tpgs for treating cancer
HK40055088A (en) Thiostrepton and vitamin e-tpgs for treating cancer
CN110548145A (zh) 治疗胰腺癌的药物组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200720

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210901

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220103

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220318

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220318

End annual number: 3

Start annual number: 1

PG1601 Publication of registration